Corinne Spilios
Directeur Général chez Orano Recyclage SAS
Profil
Corinne Spilios currently works for Orano Med SAS as a Member-Governors Board member.
She is currently working for Orano Recyclage SAS as a General Manager, a position she started in 2023.
Postes actifs de Corinne Spilios
| Sociétés | Poste | Début |
|---|---|---|
Orano Med SAS
 Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Directeur/Membre du Conseil | - |
Orano Recyclage SAS
 Orano Recyclage SAS Miscellaneous Commercial ServicesCommercial Services Orano Recyclage SAS engages in the production and transformation of nuclear materials. The company is based in La Hague, France. The French company is ultimately controlled by the Government of France. | Directeur Général | 24/10/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Health Technology |
Orano Recyclage SAS
Orano Recyclage SAS Miscellaneous Commercial ServicesCommercial Services Orano Recyclage SAS engages in the production and transformation of nuclear materials. The company is based in La Hague, France. The French company is ultimately controlled by the Government of France. | Commercial Services |
